Results 271 to 280 of about 2,171,591 (317)
Some of the next articles are maybe not open access.
Current Opinion in Pharmacology, 2002
The inhibition of integrins--cell surface receptors with a crucial role in angiogenesis, tumour cell survival, invasion and metastases--has centred on the alpha(v)beta3 integrin. Work has culminated in two antagonists that are in clinical trials as cancer therapeutics. Other integrins appear to be candidate targets in the light of gene knockout studies.
openaire +2 more sources
The inhibition of integrins--cell surface receptors with a crucial role in angiogenesis, tumour cell survival, invasion and metastases--has centred on the alpha(v)beta3 integrin. Work has culminated in two antagonists that are in clinical trials as cancer therapeutics. Other integrins appear to be candidate targets in the light of gene knockout studies.
openaire +2 more sources
Seminars in Hematology, 2006
The majority of direct costs associated with caring for patients with hemophilia are attributed to replacement therapy with clotting factor concentrates (CFC). For patients who develop high-titer inhibitors, CFC are ineffective and bypassing therapy is used to achieve hemostasis, thus changing the direct costs associated with treatment.
openaire +2 more sources
The majority of direct costs associated with caring for patients with hemophilia are attributed to replacement therapy with clotting factor concentrates (CFC). For patients who develop high-titer inhibitors, CFC are ineffective and bypassing therapy is used to achieve hemostasis, thus changing the direct costs associated with treatment.
openaire +2 more sources
Cellular and Molecular Life Sciences, 2015
Autophagy is a lysosome-dependent mechanism of intracellular degradation. The cellular and molecular mechanisms underlying this process are highly complex and involve multiple proteins, including the kinases ULK1 and Vps34. The main function of autophagy is the maintenance of cell survival when modifications occur in the cellular environment.
openaire +2 more sources
Autophagy is a lysosome-dependent mechanism of intracellular degradation. The cellular and molecular mechanisms underlying this process are highly complex and involve multiple proteins, including the kinases ULK1 and Vps34. The main function of autophagy is the maintenance of cell survival when modifications occur in the cellular environment.
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2012
Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its role in mitosis is an area of continued interest.
Susana M, Campos, Don S, Dizon
openaire +2 more sources
Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its role in mitosis is an area of continued interest.
Susana M, Campos, Don S, Dizon
openaire +2 more sources
2016
he use of corrosion inhibitors represents an important option for the control of corrosion processes and for providing corrosion protection to different metals. Inhibitors have been widely used for corrosion control. They can be employed in solution in order to control the aggressiveness of a corrosive media.
ANDREATTA, Francesco, FEDRIZZI, Lorenzo
openaire +2 more sources
he use of corrosion inhibitors represents an important option for the control of corrosion processes and for providing corrosion protection to different metals. Inhibitors have been widely used for corrosion control. They can be employed in solution in order to control the aggressiveness of a corrosive media.
ANDREATTA, Francesco, FEDRIZZI, Lorenzo
openaire +2 more sources
Current Pharmaceutical Design, 2013
Chymase, a chymotrypsin-like serine protease that is abundant in secretory granules from mast cells, has been identified to be a key enzyme in the local renin-angiotensin system (RAS) that generates angiotensin II (Ang II) independent of angiotensin converting enzyme (ACE).
Eiji, Yahiro +4 more
openaire +2 more sources
Chymase, a chymotrypsin-like serine protease that is abundant in secretory granules from mast cells, has been identified to be a key enzyme in the local renin-angiotensin system (RAS) that generates angiotensin II (Ang II) independent of angiotensin converting enzyme (ACE).
Eiji, Yahiro +4 more
openaire +2 more sources
Seminars in Hematology, 2006
Inhibitory antibodies that develop in patients with hemophilia render standard therapy with factor concentrates ineffective. Several factors may influence inhibitor incidence, including genetics, the type of factor concentrate, and environment. A higher incidence of inhibitors in siblings compared to extended relatives, and in African Americans ...
openaire +2 more sources
Inhibitory antibodies that develop in patients with hemophilia render standard therapy with factor concentrates ineffective. Several factors may influence inhibitor incidence, including genetics, the type of factor concentrate, and environment. A higher incidence of inhibitors in siblings compared to extended relatives, and in African Americans ...
openaire +2 more sources
Enzymatic Inhibitors (Protease inhibitors, Amylase inhibitors, Cholinesterase Inhibitors)
2022Varun Kumar, Kanwate Balaji
openaire +1 more source
The Lancet, 2001
Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE). They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II.
openaire +2 more sources
Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE). They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II.
openaire +2 more sources
2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources